The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Inclusion Criteria: * Body mass index (BMI) 18 to 35 kg/m\^2 * Nonsmoker and/or have not used nicotine or nicotine-containing products for at least 3 months prior to enrollment * Estimated glomerular filtration rate (eGFR) 30 to 60 mL/min/1.73 m\^2 Exclusion Criteria: * History of stroke, chronic seizures, or major neurological disorder * Ongoing, clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, respiratory, or genitourinary abnormalities or diseases * Systolic blood pressure (SBP) ≤95 mmHg or \>160 mmHg, or diastolic blood pressure (DBP) ≤45 mmHg or \>95 mmHg * History of neoplastic disease except for adequately treated non-melanomatous skin carcinoma * Unable to refrain from, or anticipates the use of, strong/moderate cytochrome P450 3A4 (CYP3A4) inhibitors * Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages, wine, or distilled spirits per day * Consumes excessive amounts of caffeine, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day * Had major surgery or donated blood within 8 weeks prior to enrollment * Has participated in another investigational study within 4 weeks prior * History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food * Currently a regular user of illicit drugs, or has a history of drug (including alcohol) abuse within approximately 6 months * Has active or has a history of nephrolithiasis * Has had a kidney removed or has a functioning renal transplant